MedImmune
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, MedImmune sits in the top decile of US sponsors by registered trial count (#151 of 15,742 sponsors by registered trial count).
MedImmune: 210 sponsored US clinical trials, none currently recruiting.
MedImmune sponsors 210 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 185 completed. 27 of these trials are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 9 trials.
Top-decile sponsor footprint
MedImmune ranks in the top decile of sponsors by registered trial count (#151 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
185 of 203 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
210 total, page 2 of 5
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
NCT02200770
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
NCT02340975
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
NCT02318394
Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis
NCT02347176
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
NCT02290340
A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults
NCT02289820
Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults
NCT02350751
Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
NCT02271945
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer
NCT02262741
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
NCT02261220
Study of the Efficacy and Safety of MEDI4893
NCT02296320
A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
NCT02221960
Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults
NCT02255760
A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
NCT02205333
Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
NCT02227108
Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis
NCT02277574
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
NCT02117219
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
NCT02118337
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults
NCT02114268
A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults
NCT02115815
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
NCT02088112
A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers
NCT02085473
Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age
NCT01985997
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
NCT02027961
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
NCT02013804
Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
NCT02054130
A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age
NCT01997450
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
NCT02000947
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
NCT01859143
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
NCT01829711
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis
NCT01878123
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
NCT01753193
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
NCT01769417
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
NCT01629667
A Phase 1/2 Study to Evaluate MEDI4736
NCT01693562
A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
NCT01579916
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
NCT01585766
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
NCT01577745
Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease
NCT01554800
MEDI-557 Adult Dosing
NCT01562938
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT01453205
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT01466153
MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
NCT01498952
A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus
NCT01438489
A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers
NCT01544361
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
NCT01544348
A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
NCT01448850
A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
NCT01402986
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
NCT01446159
A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus
NCT01283139
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 106 |
| Phase 2 | 58 |
| Phase 3 | 12 |
| Phase 4 | 15 |
How the MedImmune early-phase archive is shaped
210 indexed studies, none listed as recruiting (0% open); 185 completed (88%).
Phase mix: 27 late (III/IV) vs 164 early (I/II) (early-phase heavy).
Top condition: Healthy (9 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
MedImmune: archived-pipeline peers nationwide
Peers matched on 210 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
MedImmune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 210 archived trials
- OHSU Knight Cancer Institute · 211 trials · 17% recruiting
- University of Louisville · 217 trials · 21% recruiting
- National Center for Complementary and Integrative Health (NCCIH) · 203 trials · 3% recruiting
- The University of Texas Medical Branch, Galveston · 203 trials · 14% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this MedImmune page
210 registered trials is a research-attention snapshot, not an endorsement of MedImmune or any single study.
- None of MedImmune's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy is the condition MedImmune studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
MedImmune pipeline card: 210 registered trials from official public datasets.Report a data error.